Supplementary Figure 1 Lewis, et al.

Cell Death (Ramos) Untreated Proliferation (Ramos) hIgG (crosslinked) Dacetuzumab (soluble) Dacetuzumab (crosslinked) Percent Cell Death (apoptotic + necrotic) Crosslinking Ab Dacetuzumab (soluble) hIgG (crosslinked) Dacetuzumab (crosslinked) CD40 Ligand hIgG (soluble) Untreated mg/ml 1 3 10 1 3 10 10 10 20 1 ng/ml phospho-ERK1/2 MAPK Dacetuzumab (crosslinked) phospho-p38 MAPK IkB-a Dacetuzumab phospho-AKT Untreated 1.00x103 Lane: 1 2 3 4 5 6 7 8 9 10 11 4.12 12.3 37.0 111 333 ng/ml phospho-ERK1/2 MAPK b-Actin Ramos a Dacetuzumab Signaling (RL) b c Supplementary Figure 1 Lewis, et al.

Supplementary Figure 1 Lewis, et al.

Supplementary Figure 1 Lewis, et al.

Presentation Transcript

Supplementary Figure 4 Hori et al.

Supplementary Figure 7 Hori et al.

Thiruchelvam et al Supplementary Figure 4

Mertens et al., Supplementary Figure

Supplementary Figure S1 Wang et. al.

Nakayama et al. , Supplementary Figure 3

Perugini et al Supplementary Figure 1

Farmer et al Supplementary Figure 1

Supplementary Figure 1. Suzuki et al.

Yoon et al. Supplementary Figure S4

Supplementary Figure 1 Logan et al

Supplementary Figure S1, Schneider et al

Yang et al. Supplementary Figure S1

Oiva et al., Supplementary Figure.

Supplementary Figure 5. Nikolova et al

Supplementary Figure 1_Van Looy et al.

Sansone et al, Supplementary Figure 2

Gentile et al., Supplementary Figure 6

Supplementary figure 1 Palacios et. al

Supplementary Figure 1- FUJIMURA et al.